Denali Advisors LLC Makes New $129,000 Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Denali Advisors LLC bought a new position in Organogenesis Holdings Inc. (NASDAQ:ORGO) during the 1st quarter, Holdings Channel reports. The institutional investor bought 45,500 shares of the company’s stock, valued at approximately $129,000.

Several other large investors have also recently added to or reduced their stakes in ORGO. Los Angeles Capital Management LLC grew its stake in Organogenesis by 45.9% in the first quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company’s stock worth $1,422,000 after purchasing an additional 157,575 shares in the last quarter. Cornerstone Investment Partners LLC bought a new stake in shares of Organogenesis during the fourth quarter valued at approximately $257,000. Jump Financial LLC bought a new stake in Organogenesis during the fourth quarter worth approximately $185,000. Bailard Inc. bought a new stake in Organogenesis during the fourth quarter worth approximately $147,000. Finally, Palumbo Wealth Management LLC bought a new stake in Organogenesis during the fourth quarter worth approximately $46,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Lake Street Capital started coverage on shares of Organogenesis in a research report on Friday, June 28th. They issued a “buy” rating and a $5.00 price target on the stock.

Organogenesis Stock Performance

Shares of ORGO traded up $0.13 during trading hours on Wednesday, reaching $2.79. 235,906 shares of the company traded hands, compared to its average volume of 959,463. The stock’s fifty day moving average is $2.62 and its 200 day moving average is $3.11. The stock has a market cap of $369.87 million, a P/E ratio of 66.52 and a beta of 1.65. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.41 and a current ratio of 2.74. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.01. Organogenesis had a net margin of 1.34% and a return on equity of 2.11%. The firm had revenue of $109.98 million for the quarter, compared to analysts’ expectations of $100.44 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. Equities research analysts anticipate that Organogenesis Holdings Inc. will post -0.05 earnings per share for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.